Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7096 to 7110 of 7675 results

  1. Epilepsy in adults (QS26)

    This quality standard has been updated and replaced by NICE quality standard 211. 

    Quality standard
    Published
    28 February 2013

  2. Epilepsy in children and young people (QS27)

    This quality standard has been updated and replaced by NICE quality standard 211. 

    Quality standard
    Published
    28 February 2013

  3. Venous thromboembolism in adults: diagnosis and management (QS29)

    This quality standard has been updated and replaced by NICE quality standard QS201.

    Quality standard
    Last updated
    25 January 2021

  4. Venous thromboembolism in adults: reducing the risk in hospital (QS3)

    This quality standard has been updated and replaced by NICE quality standard QS201.

    Quality standard
    Last updated
    21 March 2018

  5. Dementia: independence and wellbeing (QS30)

    This quality standard has been updated and replaced by NICE quality standard 184. 

    Quality standard
    Published
    3 April 2013

  6. Smoking: supporting people to stop (QS43)

    This quality standard has been updated and replaced by NICE quality standard 207.

    Quality standard
    Last updated
    30 November 2021

  7. Neonatal specialist care (QS4)

    This quality standard has been withdrawn. Specialist neonatal care is covered in the NICE quality standards for specialist neonatal respiratory care for babies born pre-term, developmental follow-up of children and young people born preterm, maternal and child nutrition and postnatal care.

    Quality standard
    Published
    7 October 2010

  8. Rituximab for aggressive non-Hodgkin's lymphoma (TA65)

    After consultation the guidance has been withdrawn because it is no longer relevant to clinical practice. Rituximab is now routinely used outside its licensed indication. See NICE’s guideline on non-Hodgkin’s lymphoma.

    Technology appraisal guidance
    Published
    24 September 2003

  9. Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer (TA831)

    This guidance has been updated and replaced by NICE technology appraisal guidance 887.

    Technology appraisal guidance
    Published
    5 October 2022

  10. Drotrecogin alfa (activated) for severe sepsis (TA84)

    November 2011 On 25 October 2011, Eli Lilly and Company announced the withdrawal of its Xigris (drotrecogin alfa [activated]) product in all markets following results of the PROWESS–SHOCK study, which showed the study did not meet the primary endpoint of a statistically significant reduction in 28-day all-cause mortality in patients with septic shock. The company is working with regulatory agencies on this withdrawal, and is in the process of notifying healthcare professionals and clinical trial investigators. As a result of this, NICE has withdrawn its guidance on the use of drotrecogin alfa (activated) for severe sepsis.

    Technology appraisal guidance
    Published
    22 September 2004

  11. The clinical effectiveness and cost effectiveness of technologies for the secondary prevention of osteoporotic fractures in postmenopausal women (TA87)

    This guidance has been updated and replaced NICE technology appraisal guidance 161.

    Technology appraisal guidance
    Published
    26 January 2005

  12. Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer (TA885)

    This guidance has been updated and replaced by NICE technology appraisal guidance 939.

    Technology appraisal guidance
    Published
    3 May 2023

  13. The use of autologous chondrocyte implantation for the treatment of cartilage defects in the knee joints (TA89)

    This guidance has been updated and replaced by NICE technology appraisal guidance 477. 

    Technology appraisal guidance
    Published
    25 May 2005

  14. Immunosuppressive therapy for renal transplantation in adults (TA85)

    This guidance has been updated and replaced by NICE technology appraisal guidance 481.

    Technology appraisal guidance
    Published
    22 September 2004

  15. Hearing disability - hearing aids (TA8)

    This guidance has been withdrawn.

    Technology appraisal guidance
    Published
    23 July 2000